-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The dosing regimen of pembrolizumab is completely based on the pharmacokinetic (PK) model from phase I-III trials
The purpose of this research is to determine the factors that affect PK and their relationship with clinical outcomes in the real environment
Aims to determine the factors that affect PK and its relationship with clinical results in the real environment
Recruited patients with advanced cancer who received pembrolizumab monotherapy (2 mg/kg Q3W or 200 mg/m2 Q3W), continuously sampled to obtain trough concentrations, generated a PK model, assessed covariate effects, and conducted internal procedures through a guided procedure Verification
immunity
Standard goodness of fit of pembrolizumab PK model
Standard goodness of fit of pembrolizumab PK modelA total of 588 serum samples were collected from 122 patients with non-small cell lung cancer ( NSCLC ), malignant pleural mesothelioma (MPM), melanoma, and urothelial cell carcinoma (UCC) for analysis
NSCLC median follow-up for 2.
For NSCLC patients and MPM patients, there is a significant reverse CL-OS relationship
In summary, the high inter-patient variability of pembrolizumab pharmacokinetics is determined by BSA and serum albumin (on CL) and LDH (on Vd)
Among patients with high Paim monoclonal antibody pharmacokinetic variability by BSA and serum albumin (in CL) and LDH (on Vd) determined NSCLC and MPM patients showed a strong inverse relationship between CL-OS can not All patients use the same dose of pembrolizumab, and individual application doses need to be explored
Original source:
Original source:Hurkmans Daan P,Sassen Sebastiaan DT,de Joode Karlijn et al.
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
in this message
